Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment

被引:12
作者
Blake, Maja K. [1 ]
O'Connell, Patrick [1 ]
Aldhamen, Yasser A. [1 ]
机构
[1] Michigan State Univ, Coll Osteopath Med, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA
关键词
CD8(+) T cell; epigenetics; tumor microenvironment; TOX; SLAMF7; PD-1; HDAC; ATAC-seq; NIVOLUMAB PLUS IPILIMUMAB; TRANSCRIPTION FACTOR; CHROMATIN STATES; TARGETING EZH2; RNA-SEQ; CANCER; DIFFERENTIATION; EXPRESSION; GENE; YY1;
D O I
10.3389/fcell.2022.1082195
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In the setting of chronic antigen exposure in the tumor microenvironment (TME), cytotoxic CD8(+) T cells (CTLs) lose their immune surveillance capabilities and ability to clear tumor cells as a result of their differentiation into terminally exhausted CD8(+) T cells. Immune checkpoint blockade (ICB) therapies reinvigorate exhausted CD8(+) T cells by targeting specific inhibitory receptors, thus promoting their cytolytic activity towards tumor cells. Despite exciting results with ICB therapies, many patients with solid tumors still fail to respond to such therapies and patients who initially respond can develop resistance. Recently, through new sequencing technologies such as the assay for transposase-accessible chromatin with sequencing (ATAC-seq), epigenetics has been appreciated as a contributing factor that enforces T cell differentiation toward exhaustion in the TME. Importantly, specific epigenetic alterations and epigenetic factors have been found to control CD8(+) T cell exhaustion phenotypes. In this review, we will explain the background of T cell differentiation and various exhaustion states and discuss how epigenetics play an important role in these processes. Then we will outline specific epigenetic changes and certain epigenetic and transcription factors that are known to contribute to CD8(+) T cell exhaustion. We will also discuss the most recent methodologies that are used to study and discover such epigenetic modulations. Finally, we will explain how epigenetic reprogramming is a promising approach that might facilitate the development of novel exhausted T cell-targeting immunotherapies.
引用
收藏
页数:12
相关论文
共 101 条
[1]   Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation [J].
Abdel-Hakeem, Mohamed S. ;
Manne, Sasikanth ;
Beltra, Jean-Christophe ;
Stelekati, Erietta ;
Chen, Zeyu ;
Nzingha, Kito ;
Ali, Mohammed-Alkhatim ;
Johnson, John L. ;
Giles, Josephine R. ;
Mathew, Divij ;
Greenplate, Allison R. ;
Vahedi, Golnaz ;
Wherry, E. John .
NATURE IMMUNOLOGY, 2021, 22 (08) :1008-+
[2]   EZH2 Inhibitors: The Unpacking Revolution [J].
Adema, Vera ;
Colla, Simona .
CANCER RESEARCH, 2022, 82 (03) :359-361
[3]   TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection [J].
Alfei, Francesca ;
Kanev, Kristiyan ;
Hofmann, Maike ;
Wu, Ming ;
Ghoneim, Hazem E. ;
Roelli, Patrick ;
Utzschneider, Daniel T. ;
von Hoesslin, Madlaina ;
Cullen, Jolie G. ;
Fan, Yiping ;
Eisenberg, Vasyl ;
Wohlleber, Dirk ;
Steiger, Katja ;
Merkler, Doron ;
Delorenzi, Mauro ;
Knolle, Percy A. ;
Cohen, Cyrille J. ;
Thimme, Robert ;
Youngblood, Benjamin ;
Zehn, Dietmar .
NATURE, 2019, 571 (7764) :265-+
[4]   Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia [J].
Baer, Maria R. ;
Kogan, Aksinija A. ;
Bentzen, Soren M. ;
Mi, Tian ;
Lapidus, Rena G. ;
Duong, Vu H. ;
Emadi, Ashkan ;
Niyongere, Sandrine ;
O'Connell, Casey L. ;
Youngblood, Benjamin A. ;
Baylin, Stephen B. ;
Rassool, Feyruz, V .
CLINICAL CANCER RESEARCH, 2022, 28 (07) :1313-1322
[5]   PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells [J].
Balanca, Camille-Charlotte ;
Salvioni, Anna ;
Scarlata, Clara-Maria ;
Michelas, Marie ;
Martinez-Gomez, Carlos ;
Gomez-Roca, Carlos ;
Sarradin, Victor ;
Tosolini, Marie ;
Valle, Carine ;
Pont, Frederic ;
Ferron, Gwenael ;
Gladieff, Laurence ;
Vergez, Sebastien ;
Dupret-Bories, Agnes ;
Mery, Eliane ;
Rochaix, Philippe ;
Fournie, Jean-Jacques ;
Delord, Jean-Pierre ;
Devaud, Christel ;
Martinez, Alejandra ;
Ayyoub, Maha .
JCI INSIGHT, 2021, 6 (02)
[6]   YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells [J].
Balkhi, Mumtaz Y. ;
Wittmann, Gabor ;
Xiong, Fang ;
Junghans, Richard P. .
ISCIENCE, 2018, 2 :105-+
[7]   Epigenetic regulation of T cell exhaustion [J].
Belk, Julia A. ;
Daniel, Bence ;
Satpathy, Ansuman T. .
NATURE IMMUNOLOGY, 2022, 23 (06) :848-860
[8]   Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms [J].
Beltra, Jean-Christophe ;
Manne, Sasikanth ;
Abdel-Hakeem, Mohamed S. ;
Kurachi, Makoto ;
Giles, Josephine R. ;
Chen, Zeyu ;
Casella, Valentina ;
Ngiow, Shin Foong ;
Khan, Omar ;
Huang, Yinghui Jane ;
Yan, Patrick ;
Nzingha, Kito ;
Xu, Wei ;
Amaravadi, Ravi K. ;
Xu, Xiaowei ;
Karakousis, Giorgos C. ;
Mitchell, Tara C. ;
Schuchter, Lynn M. ;
Huang, Alexander C. ;
Wherry, E. John .
IMMUNITY, 2020, 52 (05) :825-+
[9]   Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells [J].
Bengsch, Bertram ;
Ohtani, Takuya ;
Khan, Omar ;
Setty, Manu ;
Manne, Sasikanth ;
O'Brien, Shaun ;
Gherardini, Pier Federico ;
Herati, Ramin Sedaghat ;
Huang, Alexander C. ;
Chang, Kyong-Mi ;
Newell, Evan W. ;
Bovenschen, Niels ;
Pe'er, Dana ;
Albelda, Steven M. ;
Wherry, E. John .
IMMUNITY, 2018, 48 (05) :1029-+
[10]   Defining 'T cell exhaustion' [J].
Blank, Christian U. ;
Haining, W. Nicholas ;
Held, Werner ;
Hogan, Patrick G. ;
Kallies, Axel ;
Lugli, Enrico ;
Lynn, Rachel C. ;
Philip, Mary ;
Rao, Anjana ;
Restifo, Nicholas P. ;
Schietinger, Andrea ;
Schumacher, Ton N. ;
Schwartzberg, Pamela L. ;
Sharpe, Arlene H. ;
Speiser, Daniel E. ;
Wherry, E. John ;
Youngblood, Benjamin A. ;
Zehn, Dietmar .
NATURE REVIEWS IMMUNOLOGY, 2019, 19 (11) :665-674